Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for the exclusive commercialization rights of Zeli Mei® in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan, including 125 million yuan upfront and 65 million yuan in milestone payments [2] - Zeli Mei® is a non-hormonal innovative drug developed by Zedman, recognized as the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [3] - The collaboration is seen as a significant milestone for Zedman in market expansion and resource complementarity, aiming to enhance pediatric and dermatological treatments in China [2][3] Group 2 - Zedman’s CEO emphasized the importance of this partnership in maximizing the innovative value of Zeli Mei® and accelerating its internationalization process [3] - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product portfolio in pediatric and dermatological treatments, showcasing the strength of Chinese innovation in the dermatology field [3]

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China, excluding Hong Kong, Macau, and Taiwan [1] - Zedman will receive a maximum of 190 million yuan in upfront and milestone payments, including a maximum of 125 million yuan upfront and 65 million yuan for research milestones [1] - This collaboration marks a significant milestone in Zedman's market expansion and is a strategic move for resource complementarity and mutual benefits [1] Group 2 - Zeli Mei (Bimodamide Cream) is an innovative non-hormonal drug developed by Zedman, approved for treating eczema in children over 2 years old and adults, representing the first AhR modulator for this indication [2] - The drug works by suppressing inflammation, repairing skin barriers, regulating microbiota, and combating oxidative stress, addressing clinical pain points of traditional treatments [2] - Zedman’s CEO emphasized the importance of this partnership for maximizing the innovative value of Zeli Mei and accelerating its market promotion and clinical application in China [2] Group 3 - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product layout in pediatric and dermatological treatments, filling a clinical gap for young patients with eczema [2] - The partnership aims to leverage Jichuan's established sales network and specialized academic promotion team to expedite Zeli Mei's market entry and clinical adoption [2] - This initiative will enhance Jichuan's product matrix in pediatrics and dermatology, contributing to the development of skin health for children and adults in China [2]

Core Insights - Yuanqi Biopharmaceuticals has entered a strategic collaboration with Dr. Falk Pharma to co-develop the innovative AhR agonist ATB102 for the treatment of moderate to severe ulcerative colitis (UC) [1][2] - ATB102 is a novel mechanism therapy targeting gastrointestinal inflammation and mucosal damage, currently undergoing Phase I clinical trials in the United States [1][2] Company Overview - Yuanqi Biopharmaceuticals focuses on the research and development of new drugs for inflammatory immune diseases, while Dr. Falk Pharma specializes in the digestive and metabolic fields [1] - The collaboration includes joint development, licensing options, production, and commercialization agreements for ATB102 [1] Product Details - ATB102 is designed to be enriched in the gut, aiming to restore immune homeostasis and promote mucosal barrier repair, with potential anti-fibrotic and antioxidant effects [2] - The drug targets the AhR, a ligand-dependent transcription factor involved in immune balance and barrier function maintenance, which has been linked to inflammatory bowel diseases [2] Market Potential - The partnership allows Dr. Falk Pharma to obtain global exclusive rights for ATB102 outside of Greater China, while Yuanqi Biopharmaceuticals will receive signing fees, milestone payments, and royalties based on sales [1] - The collaboration is expected to accelerate the clinical development process, addressing unmet clinical needs in the ulcerative colitis treatment landscape [2]